Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2015 3
2016 5
2017 3
2018 6
2019 8
2020 14
2021 7
2022 19
2023 21
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.
Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E. Letson CT, et al. Among authors: binder m. Clin Cancer Res. 2023 Aug 1;29(15):2919-2932. doi: 10.1158/1078-0432.CCR-22-3929. Clin Cancer Res. 2023. PMID: 37223910 Free PMC article.
Conditional survival in multiple myeloma and impact of prognostic factors over time.
Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Hwa YL, Lin Y, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Abdallah NH, et al. Among authors: binder m. Blood Cancer J. 2023 May 15;13(1):78. doi: 10.1038/s41408-023-00852-4. Blood Cancer J. 2023. PMID: 37188699 Free PMC article.
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, Dispenzieri A, Dingli D, Fonder A, Gertz MA, Gonsalves W, Hayman SR, Hwa Y, Hobbs M, Kourelis T, Lacy MQ, Leung N, Muchtar E, Warsame R, Jevremovic D, Kyle RA, Rajkumar SV, Kumar S. Zanwar S, et al. Among authors: binder m. Am J Hematol. 2023 Oct;98(10):1540-1549. doi: 10.1002/ajh.27023. Epub 2023 Jul 8. Am J Hematol. 2023. PMID: 37421603
Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling.
Sandoval L, Mohammed Ismail W, Mazzone A, Dumbrava M, Fernandez J, Munankarmy A, Lasho T, Binder M, Simon V, Kim KH, Chia N, Lee JH, Weroha SJ, Patnaik M, Gaspar-Maia A. Sandoval L, et al. Among authors: binder m. Genes (Basel). 2023 Jun 10;14(6):1245. doi: 10.3390/genes14061245. Genes (Basel). 2023. PMID: 37372428 Free PMC article.
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Among authors: binder m. Blood Adv. 2023 Aug 22;7(16):4371-4380. doi: 10.1182/bloodadvances.2023009681. Blood Adv. 2023. PMID: 37603349 Free PMC article.
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Among authors: binder m. Blood Cancer J. 2023 Dec 11;13(1):183. doi: 10.1038/s41408-023-00957-w. Blood Cancer J. 2023. PMID: 38072941 Free PMC article. No abstract available.
Utility of flow cytometry screening before MRD testing in multiple myeloma.
Panakkal V, Lakshman A, Shi M, Olteanu H, Horna P, Timm MM, Otteson GE, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Rajkumar SV, Kumar SK, Jevremovic D. Panakkal V, et al. Among authors: binder m. Blood Cancer J. 2023 Apr 20;13(1):55. doi: 10.1038/s41408-023-00832-8. Blood Cancer J. 2023. PMID: 37080968 Free PMC article. No abstract available.
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma.
Schmidt WM, Perera ND, Buadi FK, Hayman SR, Kumar SK, Dispenzieri A, Dingli D, Cook J, Lacy MQ, Kapoor P, Leung N, Muchtar E, Warsame RM, Kourelis T, Binder M, Gonsalves WI, Hogan WJ, Gertz MA. Schmidt WM, et al. Among authors: binder m. Blood Cancer J. 2023 Aug 18;13(1):126. doi: 10.1038/s41408-023-00900-z. Blood Cancer J. 2023. PMID: 37591876 Free PMC article.
Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients.
Rajkumar S, Abdallah N, Lakshman A, Kumar S, Cook J, Binder M, Kapoor P, Dispenzieri A, Gertz M, Lacy M, Hayman S, Buadi F, Dingli D, Lin Y, Kourelis T, Warsame R, Bergsagel PL. Rajkumar S, et al. Among authors: binder m. Res Sq [Preprint]. 2023 Oct 23:rs.3.rs-3378634. doi: 10.21203/rs.3.rs-3378634/v1. Res Sq. 2023. PMID: 37961238 Free PMC article. Updated. Preprint.
Muscle and fat composition in patients with newly diagnosed multiple myeloma.
Abdallah NH, Nagayama H, Takahashi N, Gonsalves W, Fonder A, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hobbs M, Gertz MA, Binder M, Kapoor P, Warsame R, Hayman SR, Kourelis T, Hwa YL, Lin Y, Kyle RA, Rajkumar SV, Broski SM, Kumar SK. Abdallah NH, et al. Among authors: binder m. Blood Cancer J. 2023 Dec 12;13(1):185. doi: 10.1038/s41408-023-00934-3. Blood Cancer J. 2023. PMID: 38086801 Free PMC article.
79 results